Articles dans des revues avec comité de lecture (45)
  1. 1. Rediti, M., Venet, D., Joaquin Garcia, A., Maetens, M. M., Vincent, D., Majjaj, S., El-abed, S., Di Cosimo, S., Ueno, T., Izquierdo, M., Piccart-Gebhart, M., Pusztai, L., Loi, S., Salgado, R., Viale, G., Rothé, F., & Sotiriou, C. (2024). Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial. Nature communications, 15(1), 10402. doi:10.1038/s41467-024-54621-3
  2. 2. Wang, X., Venet, D., Lifrange, F., Larsimont, D., Rediti, M., Stenbeck, L., Dupont, F., Rouas, G., Garcia, A. J., Craciun, L., Buisseret, L., Ignatiadis, M., Carausu, M., Bhalla, N., Masarapu, Y., Villacampa, E. G., Franzén, L., Saarenpää, S., Kvastad, L., Thrane, K., Lundeberg, J., Rothé, F., & Sotiriou, C. (2024). Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications. Nature communications, 15(1), 10232. doi:10.1038/s41467-024-54145-w
  3. 3. Buisseret, L., Bareche, Y., Venet, D., Girard, E., Gombos, A., Emonts, P., Majjaj, S., Rouas, G., Serra, M., Debien, V., Agostinetto, E., Garaud, S., Willard-Gallo, K., Larsimont, D., Stagg, J., Rothé, F., & Sotiriou, C. (2024). The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab. ESMO Open, 9(5), 102964. doi:10.1016/j.esmoop.2024.102964
  4. 4. Fernandez-Martinez, A., Rediti, M., Tang, G., Pascual, T., Hoadley, K. K., Venet, D., Rashid, N. N., Spears, P. P., Islam, M. N., El-abed, S., Bliss, J. M., Lambertini, M. M. P. M., Di Cosimo, S., Huobe, J., Goerlitz, D., Hu, R., Lucas, P. P., Swain, S. S., Sotiriou, C., Perou, C. C., & Carey, L. L. (2024). Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2 -Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials. JAMA oncology. doi:10.1001/jamaoncol.2023.7304
  5. 5. Rediti, M., Fernandez-Martinez, A., Venet, D., Rothé, F., Hoadley, K. A., Parker, J. S., Singh, B., Campbell, J. D., Ballman, K. V., Hillman, D. W., Winer, E. P., El-Abed, S., Piccart, M., Di Cosimo, S., Symmans, W. F., Krop, I., Salgado, R., Loi, S., Pusztai, L., Perou, C. M., Carey, L. A., & Sotiriou, C. (2023). Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nature communications, 14(1), 7053. doi:10.1038/s41467-023-42635-2
  6. 6. Buisseret, L., Loirat, D., Aftimos, P., Maurer, C., Punie, K., Debien, V., Kristanto, P., Eiger, D., Goncalves, A., Ghiringhelli, F., Taylor, D., Clatot, F., Van den Mooter, T., Ferrero, J. M., Bonnefoi, H., Canon, J.-L., Duhoux, F. P., Mansi, L., Poncin, R., Barthélémy, P., Isambert, N., Denis, Z., Catteau, X., Salgado, R., Agostinetto, E., de Azambuja, E., Rothé, F., Craciun, L., Venet, D., Romano, E., Stagg, J., Paesmans, M., Larsimont, D., Sotiriou, C., Ignatiadis, M., & Piccart-Gebhart, M. (2023). Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial. Nature communications, 14(1), 7018. doi:10.1038/s41467-023-42744-y
  7. 7. Joaquin Garcia, A., Rediti, M., Venet, D., Majjaj, S., Kammler, R., Munzone, E., Gianni, L., Thürlimann, B., Láng, I., Colleoni, M. A., Loi, S., Viale, G., Regan, M. M., Buisseret, L., Rothé, F., & Sotiriou, C. (2023). Differential benefit of metronomic chemotherapy among triple negative breast cancer subtypes treated in the IBCSG Trial 22-00. Clinical cancer research. doi:10.1158/1078-0432.CCR-23-1267
  8. 8. Lengrand, J., Pastushenko, I., Vanuytven, S., Song, Y., Venet, D., Sarate, R. M., Bellina, M., Moers, V., Boinet, A., Sifrim, A., Rama, N., Ducarouge, B., Van Herck, J., Dubois, C., Scozzaro, S., Lemaire, S., Gieskes, S., Bonni, S., Collin, A., Braissand, N., Allard, J., Zindy, E., Decaestecker, C., Sotiriou, C., Salmon, I., Mehlen, P., Voet, T., Bernet, A., & Blanpain, C. (2023). Pharmacological targeting of netrin-1 inhibits EMT in cancer. Nature (London). doi:10.1038/s41586-023-06372-2
  9. 9. Wang, X.-M., Collet, L., Rediti, M., Debien, V., De Caluwé, A., Venet, D., Romano, E., Rothé, F., Sotiriou, C., & Buisseret, L. (2023). Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges. Journal of Clinical Medicine, 12(3). doi:10.3390/jcm12030953
  10. 10. Cailleux, F., Agostinetto, E., Lambertini, M., Rothé, F., Wu, H.-T., Balcioglu, M., Kalashnikova, E., Vincent, D., Viglietti, G., Gombos, A., Papagiannis, A., Veys, I., Awada, A., Sethi, H., Aleshin, A., Larsimont, D., Sotiriou, C., Venet, D., & Ignatiadis, M. (2022). Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse. JCO Precision Oncology, 6, e2200148. doi:10.1200/PO.22.00148
  11. 11. Fimereli, D., Venet, D., Rediti, M., Boeckx, B., Maetens, M., Majjaj, S., Rouas, G., Marchio, C., Bertucci, F., Mariani, O., Capra, M., Bonizzi, G., Contaldo, F., Galant, C., Van den Eynden, G., Salgado, R., Biganzoli, E., Vincent-Salomon, A., Pruneri, G., Larsimont, D., Lambrechts, D., Desmedt, C., Brown, D. N., Rothé, F., & Sotiriou, C. (2022). Timing evolution of lobular breast cancer through phylogenetic analysis. EBioMedicine, 82, 104169. doi:10.1016/j.ebiom.2022.104169
  12. 12. Rothé, F., Venet, D., Peeters, D., Rouas, G., Rediti, M., Smeets, D., Dupont, F., Campbell, P., Lambrechts, D., Dirix, L. Y., Sotiriou, C., & Ignatiadis, M. (2022). Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis. NPJ breast cancer, 8(1), 79. doi:10.1038/s41523-022-00445-7
    13. << Précédent 1 2 3 4 5 Suivant >>